Home
overview

With recent continuous developments in biotechnology, genomics and medicine, there is a high demand for more innovative and adaptive ways to design drug development programs.With adaptive design protocols becoming ever more complex, Adaptive Designs in Clinical Trials 2018 will equip you with the latest knowledge about the changing attitudes of the regulatory bodies to adaptive designs, how technology and experimental approaches will enrich your adaptive trials and how to ameliorate risks and errors in your adaptive designs.
 

Adaptive Designs in Clinical Trials 2018 will continue the discussion on recent developments and applications of state-of-the-art adaptive design techniques in clinical research. Experienced industry experts from across the globe will discuss recent real-life applications of group sequential and adaptive enrichment designs and give presentations on confirmatory designs with treatment selection and the use of basket, umbrella and platform studies in personalised medicine. Updates on the regulatory aspects and the evaluation of the use of new digital technologies in adaptive trials will also expand your knowledge of the current outlook in adaptive designs.

Benefits of attending 

  • hear exciting case studies on enrichment designs and group sequential trials from Boehringer-Ingelheim, Sanofi Aventis and H.lundbeck
  • Explore the current industry outlook and evaluate the promises and challenges of digital technology use with Amgen and Novartis
  • Discover how AstraZeneca and UCB Pharma are using Platform Trials and self adapting priors to advance their adaptive clinical trials
  • Examine how Roche and Merck KGaA are using adaptive clinical trials to produce targeted therapies

 

Hear from the experts, with presentations from:

  • Amgen
  • Novartis
  • Boehringr-Ingelheim
  • H.Lundbeck
  • Sanofi-Aventis
  • UCB pharma
  • AstraZeneca
  • Roche
  • GlaxoSmithKline
  • Merck KGaA

     



 

Who should attend
- Biostatisticians
- Clinical project managers
- Clinical research advisors
- Clinical Trials Directors
- Clinical scientists
- Statisticians
 

Amgen; AstraZeneca; Berry Consultants, LLP; Blueberry Therapeutics Ltd. ; Boehringer-Ingelheim; Debiopharm International SA; European Medicines Agency (EMA); GaBI Journal ; Grunenthal Gmbh; H. Lundbeck A/S; IPSEN; Ipsen Innovation; Johnson & Johnson; Kings College London; Livanova; Medicines Assessment; MHRA; MS Society; Novartis; Orion Pharma; Pfizer; Pfizer Global Pharmaceuticals; Roche Deutschland Holding Gmb H; Sanofi; Sanofi Aventis; Servier; Sigma-Tau Pharmaceuticals Inc; TFS, S.L. (CIF: B-60569175); Tillotts Pharma A G; Universitair Ziekenhuis Antwerpen; University College London; University Of Bath;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

9:10 Innovations in clinical trial design: Lessons learnt from adaptive designs

Christine Fletcher

Christine Fletcher, Executive Director Biostatistics, Amgen
View Bio

  • Why are adaptive designs used in clinical trials?
  • What have we learnt from adaptive designs?
  • What does the future of adaptive deigns look like?
  • Other innovations in clinical trial design
  • 9:50 MHRA: Regulatory perspective on adaptive design trials

    Beatrice  Panico

    Beatrice Panico, Medical Assessor, MHRA
    View Bio

  • Points to consider for initial Clinical Trial Authorisation (CTA) applications
  • Points to consider when submitting substantial amendments
  • Safety considerations
  • 10:30 Morning Coffee

    11:00 Real-life examples from an industry perspective: Boehringer-Ingelheim

    Frank Fleischer

    Frank Fleischer, Expert Statistician Methodology , Boehringer-Ingelheim
    View Bio

  • A confirmatory enrichment design using group-sequential and interleaving techniques
  • Comparing different adaptive enrichment designs
  • A selection design for determining the most equivalent drug formulation
  • Adaptive randomisation for cut-off determination in the early phase
  • Future areas of interest for adaptive designs in clinical development
     
  • 11:40 Evaluating digital technology in adaptive clinical trials: promises and challenges

    Alex Sverdlov

    Alex Sverdlov, Director, Statistical Scientist, Novartis
    View Bio

  • Use of digital devices (including wearables) in clinical research
  • How to make sense of the data collected from digital devices
  • What experimental designs are appropriate for evaluating digital therapeutics
  • Examples of adaptive trials
  • 12:20 Networking Lunch

    13:20 How does the increased use of technology and novel clinical trial design impact regulatory advice and shape development of new medicines

    Bob Clay

    Bob Clay, Managing Director, Highbury Regulatory Science
    View Bio

  • How does the increased use of technology in adaptive trials impact regulatory guidance?
  • What are the regulatory bodies’ attitudes to novel adaptive clinical trials?
  • What are the challenges and opportunities with novel adaptive designs
  • How will in vitro diagnostic regulations impact the application of adaptive trials?
  • What does the future for adaptive designs, in the context of other approaches to obtaining evidence on the safety, efficacy and effectiveness look like?
     
  • 14:00 Confirmatory Adaptive Designs involving Selection

    Sue Todd

    Sue Todd, Professor of Medical Statistics, University of Reading
    View Bio

  • Summary of options for trials with treatment selection
  • Consideration of trials with subpopulation selection
  • Overview of examples of trials in practice
  • 14:40 Case Study: A Phase 2/3 Adaptive Seamless Study Design in Patients with Chronic Obstructive Pulmonary Disease (COPD).

    Daniela Casula

    Daniela Casula, Biostatistician, GSK
    View Bio

  • Study design and comparison with standard approach
  • The ‘issue’ with the interim analysis
  • Simulation plan and results
  • 15:20 Afternoon Tea

    15:50 Latest developments in adaptive designs: a company's perspective - Sanofi-Aventis

    Loic Darchy

    Loic Darchy, Head of Statistical Methodology Group, Sanofi Aventis

  • Overview of the latest research at Sanofi
  • Examples of how Sanofi is currently using adaptive designs in their clinical trials 
  • Current issues being faced and challenges ahead
  • 16:30 A Case Study: Sequential trials in the context of competing risks

    Corine Baayen

    Corine Baayen, Senior Biostatistician, Lundbeck Pharma
    View Bio

  • How can we evaluate competing risk data in group sequential trials?
  • A case study illustrating the state of the art, typical challenges and open issues
  • A discussion of remaining open questions
     
  • 17:10 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    9:10 Platform studies in drug development

    James Matcham

    James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca
    View Bio

  • The use of Basket and Umbrella Studies
  • Benefits of a Platform Study approach in Oncology
  • Practical challenges with Platform Studies
  • Applications in other therapeutic areas
  • 9:50 Regulatory perspectives for the planning and assessment of umbrella and basket trials

    Olivier Collignon

    Olivier Collignon, Biostatistician, European Medicines Agency (EMA)
    View Bio

  • Evaluation of the consistency of response across several sub-studies based on different conditions, pooling of the sub-studies and impact on regulatory assessment
  • The debatable necessity to control for multiplicity
  • Additional issues relating to biomarker development and integration of historical controls
     
  • 10:30 Morning Coffee

    11:00 Design and analysis of platform trials assessing multiple treatments and biomarkers

    James Wason

    James Wason, Group Leader, MRC Biostatistics Unit
    View Bio

  • How traditional trial design could be improved when treatments are expected to have different efficacy in different groups
  • A review and comparison of designs available for testing multiple treatments in multiple subgroups
  • An overview of methodology work done to address statistical issues arising when new treatments and biomarkers can be added in, including error rates, use of non-concurrent controls, planning confirmatory studies
  • A description of future research directions in this area
  • 11:40 Panel Discussion: experimental and novel approaches in adaptive designs

  • What experimental and novel approaches are being used by pharmaceutical companies?
  • Why are novel approaches used and what benefits do they bring?
  • Challenges associated with the use of novel adaptions
  • Future outlook for new experimental adaptions and novel approaches
  • Olivier Collignon

    Olivier Collignon, Biostatistician, European Medicines Agency (EMA)
    View Bio

    James Matcham

    James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca
    View Bio

    Ros Walley

    Ros Walley, Statistician, UCB Pharma
    View Bio

    12:20 Networking Lunch

    13:20 Self adapting priors

    Ros Walley

    Ros Walley, Statistician, UCB Pharma
    View Bio

  • Incorporating relevant historical information though a Bayesian informative prior is increasingly used in Early Clinical Development
  • Concern about potential prior-data conflict can lead to heavy discounting of this information
  • Instead “self-adapting priors” can be used which alter the down-weighting depending on the discrepancy between the prior and the data
     
  • 14:00 The Role of Re-randomization Tests in Adaptive Methods with Planned or Unplanned Changes

    Michael Proschan

    Michael Proschan, Mathmatical Statistician, National Institute of Allergy and Infectious Diseases
    View Bio

  • Unplanned changes can still be analysed in a valid way
  • The real null hypothesis being tested with covariate- and response-adaptive randomization
  • Temporal trends?  Re-randomization tests to the rescue!
  • Are re-randomization tests always valid?
  • 14:40 Afternoon Tea

    15:10 Right Patient, Right Design : Facilitating Personalised HealthCare with Adaptive Designs

    Chris Harbron

    Chris Harbron, Principal Statistical Scientist , Roche Products Ltd

  • Personalised HealthCare (PHC),  targeting therapies to those patients most likely to benefit is becoming increasingly important
  • During development there can be uncertainty on the optimal PHC strategy, both on the need for a biomarker and the exact definition of a biomarker
  • Adaptive designs provide an efficient way of mitigating this uncertainty whilst still maintaining the overall rigour and operating characteristics of the trial
     
  • 15:50 Adequate decision making in development programmes for targeted therapies

    Heiko Goette

    Heiko Goette, Biostatistician, Merck & Company
    View Bio

  • Development programmes for targeted therapies usually consist of early phase trial for identifying a target subgroup among several biomarker candidates followed by a confirmatory trial
  • Design options for confirmatory trial: targeted subgroup enrichment design or adaptive enrichment design
  • Results from early phase trial influence go/no go decision, choice of confirmatory trial design as well as interim decision rule of adaptive design
  • Early phase results need to be adjusted for data-driven selection to allow adequate decision making
     
  • 16:30 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Alex Sverdlov

    Alex Sverdlov

    Director, Statistical Scientist, Novartis
    Beatrice  Panico

    Beatrice Panico

    Medical Assessor, MHRA
    Christine Fletcher

    Christine Fletcher

    Executive Director Biostatistics, Amgen
    Frank Fleischer

    Frank Fleischer

    Expert Statistician Methodology , Boehringer-Ingelheim
    James Matcham

    James Matcham

    Head of Biometrics, Early Clinical Development, AstraZeneca
    Olivier Collignon

    Olivier Collignon

    Biostatistician, European Medicines Agency (EMA)

    Alex Sverdlov

    Director, Statistical Scientist, Novartis
    Alex Sverdlov

    Alex Sverdlov has worked as a statistical scientist in biopharmaceutical industry since 2007, in such companies as Novartis, Merck Serono and Bristol-Myers Squibb. He handled clinical trials in neurodegenerative diseases, metabolic disorders, ophthalmology, immunology, and oncology. Alex has been involved in active research on adaptive designs for clinical trials to improve efficiency of drug development. He edited a book “Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects” which was published by CRC Press in 2015. Alex’s most recent work involves design of proof-of-endpoint clinical trials evaluating digital technology (including wearable devices) in neuroscience.

     

    Beatrice Panico

    Medical Assessor, MHRA
    Beatrice  Panico

    Maria Beatrice Panico is currently a Medical Assessor in the Clinical Trials Unit at the Medicines and Healthcare products Regulatory Agency (MHRA).
    She is a medical doctor, fully qualified in Neurology with a PhD in Neuroscience. She has extensive experience in pharmacovigilance in the pharmaceutical industry.
     

    Bob Clay

    Managing Director, Highbury Regulatory Science
    Bob Clay

    Bob Clay established a regulatory consultancy practice through Highbury Regulatory Science in 2014, supporting small/medium size companies and their investors to develop regulatory/business strategies across multiple therapeutic and geographic areas. Previously, he was VP Global Regulatory Affairs at AstraZeneca with responsible for oncology, infection and personalised healthcare. Bob is a board member of TOPRA and President during 2017; a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture (MMV). Bob has held significant leadership roles in regulatory affairs in regional and global functions at Pfizer, AstraZeneca and Kinapse.
     

    Chris Harbron

    Principal Statistical Scientist , Roche Products Ltd
    Chris Harbron

    Chris Jennison

    Professor of Statistics, University Of Bath
    Chris Jennison

    Christopher Jennison is Professor of Statistics at the University of Bath, UK. His PhD research at Cornell University concerned the sequential analysis of clinical trials and he has continued to work in this area for the past 35 years. His book with Professor Bruce Turnbull, "Group Sequential Methods with Applications to Clinical Trials", is a standard text on this topic and is widely used by practising statisticians. Professor Jennison's research is informed by experience of clinical trial analysis at the Dana Farber Cancer Institute, Boston and a broad range of consultancy with Medical Research institutes and Pharmaceutical companies.

    Christine Fletcher

    Executive Director Biostatistics, Amgen
    Christine Fletcher

    Chrissie is a Regional Head in Global Biostatistical Science at Amgen and she leads a Health Technology Assessment (HTA) Biostatistics group. Chrissie has worked in the Pharmaceutical Industry for over 25 years and has experience of developing and commercialising new medicines from a variety of therapeutic areas across all phases of clinical development.

    Chrissie is currently the Vice-President of the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI), and co-chair of the Clinical Development Expert Group for the European Federation of Pharmaceutical Industries and Associations (EFPIA).

    Chrissie is a Chartered Statistician and Chartered Scientist of the Royal Statistical Society (RSS). Chrissie has an MSc in Applied Statistics and a BSc (Hons) in Statistics with Management Science Techniques.
     

    Corine Baayen

    Senior Biostatistician, Lundbeck Pharma
    Corine Baayen

    Corine Baayen did her PhD in biostatistics and bioinformatics at H. Lundbeck A/S and the University of Copenhagen as part of the Marie Curie Initial Training Network MEDIASRES. She then continued to work as a biostatistician at the University Hospital of Nantes and later as a statistical consultant at Capionis in France. She is currently working as a senior statistician at Lundbeck in Denmark.

    Daniela Casula

    Biostatistician, GSK
    Daniela Casula

    Daniela Casula has worked as a lead biostatistician at GSK since 2016. Before this she has held Biostatistician and Senior Biostatistician roles in both Novartis and Chiesi Farmaceutici. Between 2002-2006 he worked as a Bioanalyst at Chiron. She graduadted with a masters in Statisticial and Economic Sciences in 2001 and with a 2nd level masters in Advanced Biostatistics for Clinical research in 2016.

    Frank Fleischer

    Expert Statistician Methodology , Boehringer-Ingelheim
    Frank Fleischer

    Being a trained mathematician and statistician Frank has worked for more than 10 years in the pharmaceutical industry. He is a member of the statistical methodology group at Boehringer Ingelheim. Frank is considered with methodological questions regarding adaptive designs, statistical decision making, dose finding and Bayesian data enrichment as well as with piloting these methods in clinical trials. Through this role several projects across different TAs and phases are supported. Formerly he has been a project statistician for different projects in oncology, immunology and the biosimilars.
     

    Heiko Goette

    Biostatistician, Merck & Company
    Heiko Goette

    Heiko has been a Biostatistician at Merck KGaA in Germany since 2009. Before this he spent 5 years working as a research assistant at the Institute of Medical Biostatistics, Epidemiology and Informatics, Johannes Gutenberg-University Mainz, Germany. He graduated with a Statistics major, University of Dortmund, Germany in 2004 and received his doctorate in 2008 from Johannes Gutenberg-University Mainz, Germany.
     

    James Matcham

    Head of Biometrics, Early Clinical Development, AstraZeneca
    James Matcham

    James Matcham is the Head of Early Clinical Development Biometrics at AstraZeneca. After completing his studies he began his career as a Research Fellow at the Applied Statistics Research Unit at the University of Kent, UK. He then completed 21 years at Amgen where he worked on the development and regulatory/reimbursement approval of many of their biotechnology products, representing the company at regulatory submissions in the US and the EU. James now leads the Biometrics team specialising in early clinical trial design, decisions and analysis at AstraZeneca. His interests include adaptive trial design, the application of Bayesian methods and quantitative decision making.

    James Wason

    Group Leader, MRC Biostatistics Unit
    James Wason

    James Wason currently holds a joint appointment between the MRC Biostatistics Unit (University of Cambridge) and Newcastle University. He leads a research group focused on development of statistical methods for more efficient trials. His research interests are adaptive designs, using biomarkers prospectively during trials and analysis of composite endpoints. As well as working on methodology, James is very interested in applying novel methods in real clinical trials. He’s currently involved in several ongoing trials using novel designs.

    Loic Darchy

    Head of Statistical Methodology Group, Sanofi Aventis
    Loic Darchy

    Michael Proschan

    Mathmatical Statistician, National Institute of Allergy and Infectious Diseases
    Michael Proschan

    Michael Proschan has been a Mathematical Statistician in the Biostatistics Research Branch at the National Institute of Allergy and Infectious Diseases since January of 2006. Prior to coming to NIAID, he spent about 16 years at the National Heart, Lung, and Blood Institute. He co-authored the books: Statistical Monitoring of Clinical Trials: A Unified Approach, with Gordon Lan and Janet Wittes (Springer, 2006) and Essentials of Probability Theory for Statisticians, (CRC Press, 2016) with Pamela Shaw.

    Dr. Proschan received his Ph.D. in Statistics from Florida State University in 1989, M.S. in Statistics from Stanford University in 1982, and B.S. in Statistics and Mathematics (double major) from Florida State University in 1980. He became a Fellow of the American Statistical Association in 2005.
     

    Olivier Collignon

    Biostatistician, European Medicines Agency (EMA)
    Olivier Collignon

    Dr Olivier Collignon works as biostatistician at the Luxembourg Institute of Health since 2011 and holds a PhD in Applied Mathematics since 2009. He is currently seconded at the European Medicines Agency in London since 2014, where he participates to the scientific evaluation of the design and results of clinical trials to obtain marketing authorization of new drugs in Europe. He is especially interested in adaptive designs, basket trials and historical controls and their applications to oncology. Dr Collignon has also been involved in the National Cancer Registry of Luxembourg with which he has led collaborations with the International Agency for Research on Cancer in Lyon.
    His expertise also consists in developing variable selection methods to detect promising biomarkers and build efficient clinical prediction models.
     

    Ros Walley

    Statistician, UCB Pharma
    Ros Walley

    Ros Walley studied at Cambridge University for her degree and post-graduate qualification and has worked in Pharma for over 20 years. She has supported a wide range of preclinical, clinical and biomarker areas and she is now a member of the UCB Centre for Excellence in Statistical Innovation providing statistical consultancy across the portfolio. She has a particular focus on Bayesian statistics but more generally is interested in any statistical methodology that will facilitate clear decision-marking.

    Sue Todd

    Professor of Medical Statistics, University of Reading
    Sue Todd

    Sue is Professor of Medical Statistics within the Department of Mathematics and Statistics at the University of Reading and has over 25 years’ experience as an applied academic statistician working in the fields of clinical trials and epidemiology. Her particular research areas of interest are adaptive designs and group-sequential clinical trials. Recent research has considered methodology for novel study design and analysis in these areas, in particular seamless phase II/III clinical trials involving treatment or subpopulation selection and multiple endpoints of interest.

    Tom Parke

    Director of Software Solutions, Berry Consultants, LLP
    Tom Parke

    Tom Parke is Director of Software Solutions for Berry Consultants. Tom joined Berry Consultants in 2016 and previously worked at Tessella, a UK scientific software company where he first met Don Berry in 1998 when he managed the development and running of a software system to support Pfizer’s ASTIN Stroke trial – a ground breaking response adaptive randomization dose ranging trial designed by Don and Peter Mueller.

    Following that he managed multiple projects to support different aspects of many adaptive clinical trials, mostly designed by Berry Consultants and projects to develop clinical trial simulators, first with Pfizer, then Wyeth, and finally to develop FACTS.

    Tom originally graduated with joint First Class Honors in Maths and Computer Science from Bristol University, and enjoyed two decades in the software industry before stumbling upon the wonderful world of adaptive clinical trials.

     

    Supporters

    Workshops

    Multiple Hypothesis Testing in Group Sequential and Adaptive Clinical Trials
    Workshop

    Multiple Hypothesis Testing in Group Sequential and Adaptive Clinical Trials

    Copthorne Tara Hotel
    11th April 2018
    London, United Kingdom

    Unlocking the potential of platform trials
    Workshop

    Unlocking the potential of platform trials

    Copthorne Tara Hotel
    11th April 2018
    London, United Kingdom

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Speaker Interview - Daniela Casula, Lead Statistician, GlaxoSmithKline

    Download

    SPEAKER INTERVIEW - Tom Parke, Director of Software Solutions, Berry Consulting

    Download

    SPEAKER INTERVIEW - Frank Fleischer, Expert Statistician Methodology, Boehringer-Ingelheim

    Download

    SPEAKER INTERVIEW - Alex Novartis, Director & Statistical Scientist, Novartis

    Download

    Media Partners


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Pharma Journalist

    Supporters
    http://http://www.pharmajournalist.com/

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    evvnt Ltd

    Supporters
    http://www.evvnt.com

    evvnt enables people all over the world to fill their events utilising the most effective event listing sites on the web. Every minute, with little more than a click, more events and conferences appear in listings, in search engines and on mobile - discoverable by both category and location. With next to no effort customers of evvnt get better attendance, while consumers find events they previously had no idea existed. To date customers in 70 countries worldwide have submitted over 500,000 thousand event listings, created over 300,000 live links, and generated 1 million clicks to ticketing and registration pages. Learn more at www.evvnt.com


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.